Literature DB >> 6413999

Interaction of synthetic opioid metenkephalin peptide analogs, Lilly 127623 and FK 33-824 with indole hallucinogens: antagonism of N,N-dimethyltryptamine- and LSD-induced disruption of food-rewarded bar pressing behavior in the rat.

D M Ruffing, E F Domino.   

Abstract

The selected opioid metenkephalin synthetic peptide analogs Lilly (LY) 127623 and FK 33-824 were tested for behavioral dose effects and potential interaction with N,N-dimethyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) in adult male Holtzman rats trained on a positive reinforcement fixed-ratio 4 (FR-4) behavioral bar pressing schedule, i.e., a reward of 0.01 ml sugar-sweetened evaporated milk was earned on every fourth bar press. DMT (3.2 mg/kg) and LSD (0.1 mg/kg), administered IP following a 0.9% NaCl 15-20-min control pretreatment, disrupted established food-rewarded FR-4 bar pressing in a consistent and reproducible manner. Animals pretreated IP with predetermined behaviorally noneffective doses of LY 127623 (0.01-0.32 mg/kg) and FK 33-824 (0.001-0.01 mg/kg) 15-20 min prior to receiving DMT demonstrated significant antagonism to DMT-induced disruption of FR-4 bar pressing, while doses of 0.10-0.32 mg/kg LY 127623 and 0.00032-0.0032 mg/kg FK 33-824 significantly antagonized LSD-induced behavioral effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413999     DOI: 10.1007/BF00432112

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  Interaction of LSD and other hallucinogens with dopamine-sensitive adenylate cyclase in primate brain: regional differences.

Authors:  H S Ahn; M H Makman
Journal:  Brain Res       Date:  1979-02-16       Impact factor: 3.252

Review 2.  Endogenous opiates: 1980.

Authors:  G A Olson; R D Olson; A J Kastin; D H Coy
Journal:  Peptides       Date:  1981       Impact factor: 3.750

3.  [Various aspects of the interaction between the dopamine and opiate systems in schizophrenia].

Authors:  I P Anokhina
Journal:  Vestn Akad Med Nauk SSSR       Date:  1982

Review 4.  Structure-activity relationships of phenethylamine hallucinogens.

Authors:  D E Nichols
Journal:  J Pharm Sci       Date:  1981-08       Impact factor: 3.534

Review 5.  Speculations on the mechanism of action of hallucinogenic indolealkylamines.

Authors:  R A Glennon; J A Rosecrans
Journal:  Neurosci Biobehav Rev       Date:  1981       Impact factor: 8.989

6.  Brain opiates in mental illness.

Authors:  J L Marx
Journal:  Science       Date:  1981-11-27       Impact factor: 47.728

7.  An animal behavior model for decreased central serotonergic function.

Authors:  B L Jacobs; M E Trulson
Journal:  Adv Exp Med Biol       Date:  1981       Impact factor: 2.622

8.  Serotonin receptor affinities of psychoactive phenalkylamine analogues.

Authors:  R A Glennon; S M Liebowitz; G M Anderson
Journal:  J Med Chem       Date:  1980-03       Impact factor: 7.446

9.  Increased excretion of dimethyltryptamine and certain features of psychosis: a possible association.

Authors:  R M Murray; M C Oon; R Rodnight; J L Birley; A Smith
Journal:  Arch Gen Psychiatry       Date:  1979-06

10.  Evidence of the preferential involvement of mu receptors in analgesia using enkephalins highly selective for peripheral mu or delta receptors.

Authors:  G Gacel; M C Fournié-Zaluski; E Fellion; B P Roques
Journal:  J Med Chem       Date:  1981-10       Impact factor: 7.446

View more
  2 in total

1.  Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats.

Authors:  Michael B Gatch; Margaret A Rutledge; Theresa Carbonaro; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2009-03-14       Impact factor: 4.530

Review 2.  Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.

Authors:  Steven A Barker
Journal:  Psychopharmacology (Berl)       Date:  2022-01-22       Impact factor: 4.415

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.